Evidence map›Paper›PMID 27271757›Full record

ArticlePloS one2016

A Novel Truncated Form of Serum Amyloid A in Kawasaki Disease.

John C Whitin, Tom To-Sang Yu, Xuefeng Bruce Ling, John T Kanegaye, Jane C Burns, Harvey J Cohen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Biomarkers in Primary Systemic Vasculitides: Narrative Review.International journal of molecular sciences · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. [Association of rs4638289 and rs7131332 polymorphisms of the serum amyloid A1 gene with Kawasaki disease].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020
    Article
  9. The plasma peptides of sepsis.Clinical proteomics · 2020
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

John C WhitinDepartment of Pediatrics, Stanford University, Stanford, California, United States of America.ORCID http://orcid.org/0000-0002-6229-4628
Tom To-Sang YuDepartment of Pediatrics, Stanford University, Stanford, California, United States of America.
Xuefeng Bruce LingDepartment of Surgery, Stanford University, Stanford, California, United States of America.
John T KanegayeDepartment of Pediatrics, University of California San Diego, La Jolla, California, United States of America, and Rady Children's Hospital-San Diego, San Diego, California, United States of America.
Jane C BurnsDepartment of Pediatrics, University of California San Diego, La Jolla, California, United States of America, and Rady Children's Hospital-San Diego, San Diego, California, United States of America.
Harvey J CohenDepartment of Pediatrics, Stanford University, Stanford, California, United States of America.
Stanford University · USUniversity of California San Diego · US

Funding

Genetic Markers and gene expression in Kawasaki DiseaseR01HL069413 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BURNS, JANE C · 2002 to 2010
$5.5M
Proteomic Investigations in Kawasaki DiseaseR21HL086835 · NHLBI · STANFORD UNIVERSITY · PI COHEN, HARVEY J · 2007 to 2008
$433k
NHLBI NIH HHS R01 HL069413NHLBI NIH HHS R21 HL086835
6 · The paper itself

Abstract

backgroundKawasaki disease (KD) is an acute vasculitis in children that can cause coronary artery abnormalities. Its diagnosis is challenging, and many cytokines, chemokines, acute phase reactants, and growth factors have failed evaluation as specific biomarkers to distinguish KD from other febrile illnesses. We performed protein profiling, comparing plasma from children with KD with febrile control (FC) subjects to determine if there were specific proteins or peptides that could distinguish the two clinical states. MATERIALS AND

methodsPlasma from three independent cohorts from the blood of 68 KD and 61 FC subjects was fractionated by anion exchange chromatography, followed by surface-enhanced laser desorption ionization (SELDI) mass spectrometry of the fractions. The mass spectra of KD and FC plasma samples were analyzed for peaks that were statistically significantly different.

resultsA mass spectrometry peak with a mass of 7,860 Da had high intensity in acute KD subjects compared to subacute KD (p = 0.0003) and FC (p = 7.9 x 10-10) subjects. We identified this peak as a novel truncated form of serum amyloid A with N-terminal at Lys-34 of the circulating form and validated its identity using a hybrid mass spectrum immunoassay technique. The truncated form of serum amyloid A was present in plasma of KD subjects when blood was collected in tubes containing protease inhibitors. This peak disappeared when the patients were examined after their symptoms resolved. Intensities of this peptide did not correlate with KD-associated laboratory values or with other mass spectrum peaks from the plasma of these KD subjects.

conclusionsUsing SELDI mass spectrometry, we have discovered a novel truncated form of serum amyloid A that is elevated in the plasma of KD when compared with FC subjects. Future studies will evaluate its relevance as a diagnostic biomarker and its potential role in the pathophysiology of KD.

Indexed as

Acute-Phase ReactionBiomarkersCase-Control StudiesChildChild, PreschoolCodon, NonsenseCoronary Artery DiseaseDiagnosis, DifferentialFemaleFeverHumansInfantMaleMucocutaneous Lymph Node SyndromeProtein IsoformsSerum Amyloid A ProteinBiomarkersCodon, NonsenseProtein IsoformsSerum Amyloid A Protein

Identifiers

PMID27271757
PMCPMC4894573
OpenAlexW2416184311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.